drugset / Trial / NCT00237159

Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

NCT00237159

Phase 4 Completed 284 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.

Timeline

Start
2002-10
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified

Indications